SAREPTA THERAPEUTICS, INC.

Lobbying for SAREPTA THERAPEUTICS, INC.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $230,000.00 expenses · posted Jan 20, 2026

Lobbying activity 2

Health Issues

Patient Access to Treatments Newborn Screening for Rare Diseases

Science/Technology

Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.